|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Association of Dutch Burn Centres |
|---|---|
| Collaborator: |
Dutch Burns Foundation |
| Information provided by: | Association of Dutch Burn Centres |
| ClinicalTrials.gov Identifier: | NCT00297752 |
Purpose
The face is involved in 40-50% of patients with burns admitted to the Dutch Burn Centres. Scarring of the face as a consequence of burns will often have a detrimental effect on function and aesthetics, and may cause negative effects on psychosocial wellbeing. What the best treatment is for facial burns, minimising scarring, is unclear. Besides that, there is little empirical evidence regarding the impact of facial scarring on psychosocial wellbeing.
In clinical practice good results are felt to be achieved by treatment of facial burns with flammacerium. To substantiate the perceived advantages of flammacerium, its efficacy is compared to flammazine, a current alternative of care. The efficacy of treatment will be assessed in a prospective randomised multicentre clinical trial. Efficacy will be analysed in terms of number of patients requiring surgery and functional and aesthetic outcome.
Apart from medical outcome, this study offers the opportunity to study psychosocial problems associated with facial defects. It is still an unresolved question whether facial scarring causes more or different psychosocial problems. Therefore, self-esteem and quality of life will be examined over time, in relation to depression, posttraumatic stress symptoms and other factors, such as coping style and social support.
By evaluating the efficacy of different treatment strategies, we aim to optimise the standard of care of facial burns. Furthermore, this study wants to shed more light on the psychosocial impact of facial injury. With these results psychosocial professionals will be able to focus on persons at risk and to be better able to meet a patient's personal needs.
| Condition | Intervention | Phase |
|---|---|---|
|
Burns |
Drug: ceriumnitrate silversulfadiazine (flammacerium) Drug: silversulfadiazine (flammazine) |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | A Randomised Multicentre Clinical Trial on the Efficacy of Flammacerium in the Treatment of Facial Burns and the Impact of Facial Burns on Psychosocial Wellbeing |
| Estimated Enrollment: | 180 |
| Study Start Date: | March 2006 |
| Study Completion Date: | December 2008 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Netherlands | |
| Martini Hospital, Burns centre | |
| Groningen, Netherlands, 9728 NZ | |
| Red Cross Hopsital, Burns Centre | |
| Beverwijk, Netherlands, 1942 LE | |
| Medical Centre Rijnmond South, Burns centre | |
| Rotterdam, Netherlands, 3075 EA | |
| Principal Investigator: | Nancy van Loey, PhD | Association of Dutch Burns Centres |
| Principal Investigator: | Marianne K Nieuwenhuis, PhD | Association of Dutch Burn Centres |
More Information
| Study ID Numbers: | WO/PO.109 |
| Study First Received: | February 28, 2006 |
| Last Updated: | August 7, 2009 |
| ClinicalTrials.gov Identifier: | NCT00297752 History of Changes |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
facial burns cerium flammazine quality of life randomised clinical trial |
|
Burns Anti-Infective Agents Anti-Infective Agents, Local Silver Sulfadiazine |
Therapeutic Uses Wounds and Injuries Disorders of Environmental Origin Pharmacologic Actions |